[{"id":"91d5dbc6-6dcf-4eba-8db8-c5f341150900","acronym":"GEN-602-CT-101","url":"https://clinicaltrials.gov/study/NCT03775525","created_at":"2021-01-18T18:40:37.562Z","updated_at":"2024-07-02T16:35:58.589Z","phase":"Phase 1","brief_title":"Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer","source_id_and_acronym":"NCT03775525 - GEN-602-CT-101","lead_sponsor":"Genzada Pharmaceuticals USA, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • GZ17-6.02"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 127","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-12-23"}]